
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's financial outlook is bolstered by its substantial cash position, ending the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, providing a strong foundation for continued investment in R&D and pipeline development. The positive developments surrounding BNT323, aimed at hormone receptor-positive, HER2-low metastatic breast cancer, enhance expectations for the ongoing global Phase 3 DYNASTY-Breast02 trial, which could lead to significant breakthroughs in the oncology domain. Furthermore, the emerging data on the LP.8.1-adapted monovalent COVID-19 vaccine indicates robust immune responses against multiple SARS-CoV-2 sublineages, showcasing the company's ability to adapt its vaccine portfolio in response to evolving public health needs.
Bears say
The financial outlook for BioNTech appears negative due to several fundamental risks, including negative data across multiple drug candidates in its oncology pipeline, which could adversely affect market confidence. Additionally, the company reported a net loss per diluted share of €0.12 for the third quarter of 2025, with projections indicating a full-year loss of €3.99 per share, highlighting ongoing financial challenges. Furthermore, the dynamics in the COVID-19 vaccine market pose significant headline risks that may shift investor focus away from BioNTech's oncology portfolio, complicating the company's growth trajectory.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares